Vol 12, No 2 (2021)
Case report
Published online: 2021-11-30

open access

Page views 5957
Article views/downloads 317
Get Citation

Connect on Social Media

Connect on Social Media

The use of midostaurin in aggressive systemic mastocytosis (ASM) with the c-KIT D816V mutation within The Emergency Access to Drug Technologies Programme

Alan Majeranowski12, Andrzej Mital2
Hematology in Clinical Practice 2021;12(2):84-88.

Abstract

Aggressive systemic mastocytosis (ASM) is a very rare subtype of systemic mastocytosis (SM) and, together with systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL), it belongs to advanced systemic mastocytosis (AdvSM). Different strategies of systemic treatment are used in patients with AdvSM. The protocols base on the cladribine, interferon, allogeneic hematopoietic stem cell transplantation, polychemotherapy or the midostaurin — the only approved drug therapy in AdvSM. Options available in Poland — cladribine and interferon — are characterized by a non-lasting effect and, unfortunately, midostaurin still remains unreimbursed for patients. On October 5, 2018, The Polish Agency for Health Technology Assessment and Tariff System approved the midostaurin to be financed within The Emergency Access to Drug Technologies Programme in ASM with the c-KIT D816V mutation. Based on a case report, the following manuscript describes authors’ experiences with the use of midostaurin. The aim of the article is to present an overview of the current status of midostaurin in the treatment of ASM and to summarize the results of clinical trials, focusing on its effectiveness and safety. Authors, hereby, report a case of a patient diagnosed in 2000 with cutaneous mastocytosis (CM), that developed a transformation to ASM in 2015. The following lines of treatment were used: cladribine, pegylated interferon alpha, dasatinib. Significant side effects were observed after each line, without obtaining a lasting response to treatment. In July 2020, patient began a therapy with midostaurin. Afterwards, a normalization of peripheral blood count parameters together with reduction of serum tryptase level were observed, without noticing any adverse effects.

Article available in PDF format

View PDF Download PDF file

References

  1. Valent P, Akin C, Hartmann K, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017; 77(6): 1261–1270.
  2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–2405.
  3. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016; 374(26): 2530–2541.
  4. Helbig G, Sacha T, Mital A, et al. Zaawansowana mastocytoza układowa — stanowisko ekspertów dotyczące postępowania diagnostycznego i leczniczego. Hematologia. 2019; 10(3): 113–123.
  5. Schneeweiss M, Peter B, Bibi S, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018; 103(5): 799–809.
  6. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998; 138(3): 489–495.
  7. Barete S, Lortholary O, Damaj G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015; 126(8): 1009–16; quiz 1050.
  8. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009; 84(12): 790–794.
  9. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003; 102(13): 4270–4276.
  10. Shomali W, Gotlib J. The new tool “KIT” in advanced systemic mastocytosis. Hematology Am Soc Hematol Educ Program. 2018; 2018(1): 127–136.
  11. Gotlib J, Baird JH, George TI, et al. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019; 3(15): 2264–2271.
  12. Wniosek o objęcie refundacją i ustalenie urzędowej ceny zbytu produktu leczniczego Rydapt (midostauryna) w ramach programu lekowego: „Midostauryna w leczeniu ostrej białaczki szpikowej (ICD 10 C92.0)”. Analiza weryfikacyjna. https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2019/010/AWA/010_AWA_OT.4331.1.2019_Rydapt_AML_do_publikacji_w_BIP.pdf (February 4, 2021).
  13. Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019; 94(3): 363–377.
  14. Kasamon YL, Ko CW, Subramaniam S, et al. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. Oncologist. 2018; 23(12): 1511–1519.
  15. White MK, Maher SM, Rizio AA, et al. A meta-analytic review of measurement equivalence study findings of the SF-36® and SF-12® Health Surveys across electronic modes compared to paper administration. Qual Life Res. 2018; 27(7): 1757–1767.
  16. Gotlib J, DeAngelo D, George T, et al. KIT inhibitor midostaurin exhibits a high rate of cinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood. 2010; 116(21): 316–316.
  17. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007; 37(6): 435–453.
  18. Jawhar M, Schwaab J, Naumann N, et al. Response and progression on midostaurin in advanced systemic mastocytosis: D816V and other molecular markers. Blood. 2017; 130(2): 137–145.
  19. Hartmann K, Gotlib J, Akin C, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020; 146(2): 356–366.e4.
  20. Chandesris MO, Damaj G, Lortholary O, et al. CEREMAST Study Group. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis. J Chromatogr B AnalytTechnol Biomed Life Sci. 2014; 944(26): 175–181.
  21. Charakterystyka Produktu Leczniczego. Rydapt. https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_pl.pdf (February 4, 2021).
  22. Gallogly MM, Lazarus HM, Cooper BW. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Ther Adv Hematol. 2017; 8(9): 245–261.
  23. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006; 107(2): 752–759.
  24. Valent P, Akin C, Hartmann K, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017; 28(10): 2367–2376.
  25. Szudy-Szczyrek A, Szumiło J, Krupski W, et al. Zastosowanie midostauryny w leczeniu agresywnej mastocytozy układowej — opis przypadku. Acta Haematol Pol. 2019; 50(1): S39–S45.
  26. Rogowski W, Zyśk R, Krzakowski M. Programy lekowe w onkologii. Jak optymalnie wykorzystać ich możliwości? Onkol Prakt Klin Edu. 2018; 4(5): 321–333.



Hematology in Clinical Practice